FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194547681> ?p ?o ?g. }

• W3194547681 endingPage "S11" @default.
• W3194547681 startingPage "S11" @default.
• W3194547681 abstract "Objectives: Hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to confer an overall survival (OS) benefit in a cost-effective manner when used at interval cytoreductive surgery after neoadjuvant chemotherapy for advanced ovarian cancer. Regarding the use of HIPEC at primary cytoreductive surgery (PCS), a recent multicenter retrospective cohort study demonstrated an OS advantage compared to PCS alone in women with stage III epithelial ovarian cancer (EOC). The objective of this study was to evaluate the cost-effectiveness of HIPEC in this setting. Methods: A decision analytic cost-effectiveness model of the US health care sector using simulated patients with stage III primary epithelial ovarian cancer was developed for three scenarios: 1) patients with optimal cytoreduction, 2) patients with suboptimal cytoreduction, and 3) all patients regardless of residual disease status. The base case for each model compared two surgical strategies: 1) PCS versus 2) PCS with HIPEC. Model inputs including median survival time, Kaplan-Meier estimates of OS, and costs were obtained from published studies. The time horizon was three years. The primary outcome was incremental cost-effectiveness ratio (ICER) in US dollars per life-year saved (LYS). Results: Assuming a willingness-to-pay threshold of $100,000 per LYS, PCS with HIPEC could be considered cost-effective in all three scenarios compared with PCS alone. The ICER was $9,789/LYS in optimally cytoreduced patients, $18,164/LYS in suboptimally cytoreduced patients, and $7,854/LYS for all patients regardless of residual disease burden. Conclusions: PCS with HIPEC appears to be a cost-effective strategy for patients with advanced epithelial cancer with all ICERs far below the willingness-to-pay threshold. This warrants further investigation of HIPEC in these clinical settings. Hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to confer an overall survival (OS) benefit in a cost-effective manner when used at interval cytoreductive surgery after neoadjuvant chemotherapy for advanced ovarian cancer. Regarding the use of HIPEC at primary cytoreductive surgery (PCS), a recent multicenter retrospective cohort study demonstrated an OS advantage compared to PCS alone in women with stage III epithelial ovarian cancer (EOC). The objective of this study was to evaluate the cost-effectiveness of HIPEC in this setting. A decision analytic cost-effectiveness model of the US health care sector using simulated patients with stage III primary epithelial ovarian cancer was developed for three scenarios: 1) patients with optimal cytoreduction, 2) patients with suboptimal cytoreduction, and 3) all patients regardless of residual disease status. The base case for each model compared two surgical strategies: 1) PCS versus 2) PCS with HIPEC. Model inputs including median survival time, Kaplan-Meier estimates of OS, and costs were obtained from published studies. The time horizon was three years. The primary outcome was incremental cost-effectiveness ratio (ICER) in US dollars per life-year saved (LYS). Assuming a willingness-to-pay threshold of $100,000 per LYS, PCS with HIPEC could be considered cost-effective in all three scenarios compared with PCS alone. The ICER was $9,789/LYS in optimally cytoreduced patients, $18,164/LYS in suboptimally cytoreduced patients, and $7,854/LYS for all patients regardless of residual disease burden. PCS with HIPEC appears to be a cost-effective strategy for patients with advanced epithelial cancer with all ICERs far below the willingness-to-pay threshold. This warrants further investigation of HIPEC in these clinical settings." @default.
• W3194547681 created "2021-08-30" @default.
• W3194547681 creator A5037329030 @default.
• W3194547681 creator A5044400776 @default.
• W3194547681 creator A5055415378 @default.
• W3194547681 date "2021-08-01" @default.
• W3194547681 modified "2023-09-24" @default.
• W3194547681 title "Cost-effectiveness of hyperthermic intraperitoneal chemotherapy at primary cytoreduction of epithelial ovarian cancer based on residual disease status" @default.
• W3194547681 doi "https://doi.org/10.1016/s0090-8258(21)00668-5" @default.
• W3194547681 hasPublicationYear "2021" @default.
• W3194547681 type Work @default.
• W3194547681 sameAs 3194547681 @default.
• W3194547681 citedByCount "0" @default.
• W3194547681 crossrefType "journal-article" @default.
• W3194547681 hasAuthorship W3194547681A5037329030 @default.
• W3194547681 hasAuthorship W3194547681A5044400776 @default.
• W3194547681 hasAuthorship W3194547681A5055415378 @default.
• W3194547681 hasConcept C112930515 @default.
• W3194547681 hasConcept C121608353 @default.
• W3194547681 hasConcept C126322002 @default.
• W3194547681 hasConcept C141071460 @default.
• W3194547681 hasConcept C143998085 @default.
• W3194547681 hasConcept C146357865 @default.
• W3194547681 hasConcept C151730666 @default.
• W3194547681 hasConcept C167135981 @default.
• W3194547681 hasConcept C2776694085 @default.
• W3194547681 hasConcept C2778461978 @default.
• W3194547681 hasConcept C2779458272 @default.
• W3194547681 hasConcept C2779823535 @default.
• W3194547681 hasConcept C2779900020 @default.
• W3194547681 hasConcept C2780427987 @default.
• W3194547681 hasConcept C2992773878 @default.
• W3194547681 hasConcept C2994223192 @default.
• W3194547681 hasConcept C3019080777 @default.
• W3194547681 hasConcept C64332521 @default.
• W3194547681 hasConcept C71924100 @default.
• W3194547681 hasConcept C72563966 @default.
• W3194547681 hasConcept C86803240 @default.
• W3194547681 hasConceptScore W3194547681C112930515 @default.
• W3194547681 hasConceptScore W3194547681C121608353 @default.
• W3194547681 hasConceptScore W3194547681C126322002 @default.
• W3194547681 hasConceptScore W3194547681C141071460 @default.
• W3194547681 hasConceptScore W3194547681C143998085 @default.
• W3194547681 hasConceptScore W3194547681C146357865 @default.
• W3194547681 hasConceptScore W3194547681C151730666 @default.
• W3194547681 hasConceptScore W3194547681C167135981 @default.
• W3194547681 hasConceptScore W3194547681C2776694085 @default.
• W3194547681 hasConceptScore W3194547681C2778461978 @default.
• W3194547681 hasConceptScore W3194547681C2779458272 @default.
• W3194547681 hasConceptScore W3194547681C2779823535 @default.
• W3194547681 hasConceptScore W3194547681C2779900020 @default.
• W3194547681 hasConceptScore W3194547681C2780427987 @default.
• W3194547681 hasConceptScore W3194547681C2992773878 @default.
• W3194547681 hasConceptScore W3194547681C2994223192 @default.
• W3194547681 hasConceptScore W3194547681C3019080777 @default.
• W3194547681 hasConceptScore W3194547681C64332521 @default.
• W3194547681 hasConceptScore W3194547681C71924100 @default.
• W3194547681 hasConceptScore W3194547681C72563966 @default.
• W3194547681 hasConceptScore W3194547681C86803240 @default.
• W3194547681 hasLocation W31945476811 @default.
• W3194547681 hasOpenAccess W3194547681 @default.
• W3194547681 hasPrimaryLocation W31945476811 @default.
• W3194547681 hasRelatedWork W1969454209 @default.
• W3194547681 hasRelatedWork W1979923959 @default.
• W3194547681 hasRelatedWork W2067366728 @default.
• W3194547681 hasRelatedWork W2091372359 @default.
• W3194547681 hasRelatedWork W2112625834 @default.
• W3194547681 hasRelatedWork W2164307258 @default.
• W3194547681 hasRelatedWork W2303672344 @default.
• W3194547681 hasRelatedWork W2314797785 @default.
• W3194547681 hasRelatedWork W2400048705 @default.
• W3194547681 hasRelatedWork W2954241991 @default.
• W3194547681 hasVolume "162" @default.
• W3194547681 isParatext "false" @default.
• W3194547681 isRetracted "false" @default.
• W3194547681 magId "3194547681" @default.
• W3194547681 workType "article" @default.